专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明授权

EP0686260B1 HUMAN CARCINOMA ANTIGEN (HCA), HCA ANTIBODIES, HCA IMMUNOASSAYS, METHODS OF IMAGING AND THERAPY 失效
标题翻译：人类癌抗原（HCA）HCA抗体HCA免疫分析，记录方法和治疗
公开(公告)号：EP0686260B1
公开(公告)日：2003-07-09
申请号：EP94907439.7
申请日：1994-02-07
申请人： EPIGEN, INC.
发明人： CODINGTON, John F. , HAAVIK, Svein
IPC分类号： G01N33/53 , G01N33/543 , G01N33/563 , G01N33/577 , A61K39/00 , A61K39/395 , A61K38/00 , C07K16/00
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/00 , A61K48/00 , A61K51/1078 , A61K2039/51 , A61K2123/00 , C07K14/4748 , C07K16/30 , C07K16/4266 , G01N33/57469 , G01N33/57484 , G01N33/57488 , G01N33/686 , G01N2333/705 , Y10S436/813
摘要： A glycoprotein antigen which is generally characteristic of human carcinomas, regardless of the tissue associated with the carcinoma -- human carcinoma antigen (HCA) -- and which is generally not present on normal human cells. Immunodeterminant-containing fragments of HCA substantially separated from elements of HCA's naturally occurring environment are also disclosed. HCA is generally characterized by: a) a molecular weight in excess of 750,000; b) carbohydrate moieties characteristic of mucin-type glycoproteins and comprising a relatively high proportion of sialic acid, galactose, and N-acetygalactosamine residues (e.g., at least 50 % of the carbohydrate residues are sialic acid, galactose, or N-acetylgalactosamine residues); c) an isoelectric point below pH 3.0; d) presence generally on human carcinoma cells; e) absence generally from non-transformed human cells; f) at least one immunodeterminant that specifically reacts with anti-murine epiglycanin antibody AE3; and g) general insolubility in aqueous fluids (e.g., a phosphoric acid or an HC1 solution) below pH 2.0. Also disclosed are antibodies to HCA, immunoassays for HCA, in vivo imaging using HCA-binding antibodies and therapeutics using HCA or anti-idiotypic HCA antibodies.

52. 发明公开

EP0837696A1 IMPROVED DELIVERY OF DIAGNOSTIC AND THERAPEUTIC AGENTS TO A TARGET SITE 失效
标题翻译：到目的地的诊断和治疗物质的改进的通讯
公开(公告)号：EP0837696A1
公开(公告)日：1998-04-29
申请号：EP96918023.0
申请日：1996-06-07
申请人： Immunomedics, Inc.
发明人： GRIFFITHS, Gary, L. , HANSEN, Hans, J. , GOVINDAN, Serengulam
IPC分类号： A61K38 , A61K39 , A61K41 , A61K45 , A61K47 , A61K49 , A61K51 , G01N33
CPC分类号： B82Y5/00 , A61K41/0095 , A61K47/665 , A61K47/6893 , A61K47/6897 , A61K47/6898 , A61K49/0017 , A61K51/1078 , A61K51/1093 , A61K2121/00 , A61K2123/00 , G01N33/531 , G01N33/534 , G01N33/574 , G01N33/686 , Y10S424/90
摘要： An in vivo method for delivering a diagnostic or therapeutic agent to a target site in a mammal, wherein a targeting species including a targeting moiety and a diagnostic or therapeutic agent or a binding site for a subsequently administered diagnostic or therapeutic agent conjugate, the targeting moiety having a primary binding site whereby it specifically binds to the target, is administered and allowed to accrete at the target site, is improved by injecting into the circulatory system of the mammal a clearing agent that binds to the primary binding site of the targeting species, whereby non-localized primary targeting species is cleared from circulation. The method is especially useful in pretargeting methods because the clearing agent does not remove the primary targeting species or block secondary binding sites of the primary targeting species.

53. 发明申请

WO2007019376A2 METHODS AND COMPOSITIONS FOR DIAGNOSIS OF IGA-AND IGM-MEDIATED KIDNEY DISEASES 审中-公开
标题翻译：用于诊断IGA和IGM介导的KIDNEY疾病的方法和组合物
公开(公告)号：WO2007019376A2
公开(公告)日：2007-02-15
申请号：PCT/US2006030583
申请日：2006-08-03
申请人： RQ BIOSCIENCE INC , NEW ENGLAND MEDICAL CENTER INC , QIU ROBERT SIDONG , QIU JIAZHOU , PLAUT ANDREW G
发明人： QIU ROBERT SIDONG , QIU JIAZHOU , PLAUT ANDREW G
IPC分类号： A61K51/00
CPC分类号： A61K51/081 , A61K49/00 , A61K49/085 , A61K49/14 , A61K49/143 , A61K49/16 , A61K51/0491 , A61K51/08 , A61K51/088 , A61K51/1078 , A61K51/1096 , G01N33/534 , G01N33/58 , G01N33/6893 , G01N2800/347
摘要： The present invention features noninvasive methods for diagnosing IgA or IgM kidney disorders, such as IgA nephropathy, Henoch-Schdnlein purpura, and IgM nephropathy, in a mammal. The invention also features compositions and kits useful in diagnosing these disorders.
摘要翻译：本发明的特征在于哺乳动物中用于诊断IgA或IgM肾脏疾病的非侵入性方法，例如IgA肾病，亨氏 - 切德宁紫癜和IgM肾病。本发明还具有用于诊断这些疾病的组合物和试剂盒。

54. 发明申请

WO2004041067A3 PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC DISEASE 审中-公开
标题翻译：预防和治疗综合性疾病
公开(公告)号：WO2004041067A3
公开(公告)日：2006-12-28
申请号：PCT/US0334527
申请日：2003-10-31
申请人： ELAN PHARM INC , UNIV CALIFORNIA
发明人： SCHENK DALE B , MASLIAH ELIEZER
IPC分类号： A01N37/18 , A61B20060101 , A61B1/00 , A61K38/00 , A61K38/17 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/48 , A61K51/10 , A61P25/16 , A61P25/28 , C07K2/00 , C07K4/00 , C07K5/00 , C07K14/00 , C07K17/00 , C12Q1/00 , C12Q1/02 , G01N33/53
CPC分类号： A61K39/0007 , A61K38/1709 , A61K45/06 , A61K51/1078 , A61K2039/55566
摘要： The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
摘要翻译：本发明提供用于治疗与突触核蛋白病相关疾病（包括患者脑中的α-突触核蛋白的路易体）的改进剂和方法。这种方法需要对路易体诱导有益的免疫原性应答的给药剂。该方法对帕金森病的预防和治疗特别有用。

55. 发明申请

WO1996040245A1 IMPROVED DELIVERY OF DIAGNOSTIC AND THERAPEUTIC AGENTS TO A TARGET SITE 审中-公开
标题翻译：改进诊断和治疗药物到目标网站
公开(公告)号：WO1996040245A1
公开(公告)日：1996-12-19
申请号：PCT/US1996008696
申请日：1996-06-07
申请人： IMMUNOMEDICS, INC.
发明人： IMMUNOMEDICS, INC. , GRIFFITHS, Gary, L. , HANSEN, Hans, J. , GOVINDAN, Serengulam
IPC分类号： A61K39/395
CPC分类号： B82Y5/00 , A61K41/0095 , A61K47/665 , A61K47/6893 , A61K47/6897 , A61K47/6898 , A61K49/0017 , A61K51/1078 , A61K51/1093 , A61K2121/00 , A61K2123/00 , G01N33/531 , G01N33/534 , G01N33/574 , G01N33/686 , Y10S424/90
摘要： An in vivo method for delivering a diagnostic or therapeutic agent to a target site in a mammal, wherein a targeting species including a targeting moiety and a diagnostic or therapeutic agent or a binding site for a subsequently administered diagnostic or therapeutic agent conjugate, the targeting moiety having a primary binding site whereby it specifically binds to the target, is administered and allowed to accrete at the target site, is improved by injecting into the circulatory system of the mammal a clearing agent that binds to the primary binding site of the targeting species, whereby non-localized primary targeting species is cleared from circulation. The method is especially useful in pretargeting methods because the clearing agent does not remove the primary targeting species or block secondary binding sites of the primary targeting species.
摘要翻译：用于将诊断或治疗剂递送至哺乳动物的靶位点的体内方法，其中包括靶向部分和诊断或治疗剂的靶向物质或用于随后施用的诊断或治疗剂缀合物的结合位点靶向部分通过向哺乳动物的循环系统注射与靶向物种的主要结合位点结合的结合剂，改善其具有与靶标特异性结合的主要结合位点，并且允许其在目标位点被吸收，从而非局部化的主要靶向物质从循环中清除。该方法在预靶向方法中特别有用，因为清除剂不除去主要靶向物种的主要靶向物种或阻断二级结合位点。

56. 发明申请

WO1994018562A1 HUMAN CARCINOMA ANTIGEN (HCA), HCA ANTIBODIES, HCA IMMUNOASSAYS, METHODS OF IMAGING AND THERAPY 审中-公开
标题翻译：人类癌症抗体（HCA），HCA抗体，HCA免疫测定，成像和治疗方法
公开(公告)号：WO1994018562A1
公开(公告)日：1994-08-18
申请号：PCT/US1994001379
申请日：1994-02-07
申请人： EPIGEN, INC.
发明人： EPIGEN, INC. , CODINGTON, John, F. , HAAVIK, Svein
IPC分类号： G01N33/53
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/00 , A61K48/00 , A61K51/1078 , A61K2039/51 , A61K2123/00 , C07K14/4748 , C07K16/30 , C07K16/4266 , G01N33/57469 , G01N33/57484 , G01N33/57488 , G01N33/686 , G01N2333/705 , Y10S436/813
摘要： A glycoprotein antigen which is generally characteristic of human carcinomas, regardless of the tissue associated with the carcinoma -- human carcinoma antigen (HCA) -- and which is generally not present on normal human cells. Immunodeterminant-containing fragments of HCA substantially separated from elements of HCA's naturally occurring environment are also disclosed. HCA is generally characterized by: a) a molecular weight in excess of 750,000; b) carbohydrate moieties characteristic of mucin-type glycoproteins and comprising a relatively high proportion of sialic acid, galactose, and N-acetygalactosamine residues (e.g., at least 50 % of the carbohydrate residues are sialic acid, galactose, or N-acetylgalactosamine residues); c) an isoelectric point below pH 3.0; d) presence generally on human carcinoma cells; e) absence generally from non-transformed human cells; f) at least one immunodeterminant that specifically reacts with anti-murine epiglycanin antibody AE3; and g) general insolubility in aqueous fluids (e.g., a phosphoric acid or an HC1 solution) below pH 2.0. Also disclosed are antibodies to HCA, immunoassays for HCA, in vivo imaging using HCA-binding antibodies and therapeutics using HCA or anti-idiotypic HCA antibodies.
摘要翻译：通常是人类癌症特征性的糖蛋白抗原，不管与癌 - 人癌抗原（HCA）相关的组织如何，并且其通常不存在于正常人细胞上。还公开了与HCA天然存在环境的元素基本分离的HCA的含有免疫球蛋白的片段。 HCA的特征通常是：a）分子量超过75万; b）粘蛋白型糖蛋白特征性的碳水化合物部分并且包含较高比例的唾液酸，半乳糖和N-乙酰半乳糖胺残基（例如，至少50％的碳水化合物残基是唾液酸，半乳糖或N-乙酰半乳糖胺残基） ; c）低于pH3.0的等电点; d）一般存在于人类癌细胞上; e）通常来自未转化的人细胞的缺失; f）至少一种与抗鼠表不但抗体AE3特异性反应的免疫决定剂; 和g）在低于pH2.0的水溶液（例如磷酸或HCl溶液）中的一般不溶性。还公开了针对HCA的抗体，HCA的免疫测定，使用HCA结合抗体的体内成像和使用HCA或抗独特型HCA抗体的治疗剂。

57. 发明申请

WO2016016329A1 RADIO-LABELLED ANTIBODY FRAGMENTS FOR USE IN THE PROGNOSIS, DIAGNOSIS OF CANCER AS WELL AS FOR THE PREDICTION OF CANCER THERAPY RESPONSE 审中-公开
标题翻译：用于预防用于预防癌症的无线标签抗体片段，用于预测癌症治疗反应
公开(公告)号：WO2016016329A1
公开(公告)日：2016-02-04
申请号：PCT/EP2015/067424
申请日：2015-07-29
申请人： VRIJE UNIVERSITEIT BRUSSEL
发明人： LAHOUTTE, Tony , DEVOOGDT, Nick , KEYAERTS, Marleen
IPC分类号： A61K51/10 , A61P35/00
CPC分类号： A61K51/1051 , A61K51/1045 , A61K51/1069 , A61K51/1072 , A61K51/1078 , C07K16/30 , C07K16/3015 , C07K16/32 , C07K2317/35 , C07K2317/565 , C07K2317/569 , C07K2317/92 , G01N33/57415 , G01N33/5748 , G01N2333/82
摘要： The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (V HH ) or a functional fragment thereof, wherein said V HH or a functional fragment thereof specifically binds to a target protein that is present on and/or specific for a solid tumor, e.g. HER2. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions, that comprise such polypeptides, nucleic acids and/or host cells. The application further provides such polypeptides, nucleic acids, host cells and/or compositions, for use in methods for detection, imaging, prognosis and diagnosis of cancer as well as for predicting patient response(s) to therapeutics.
摘要翻译：该应用提供包含或基本上由重链抗体（VHH）或其功能片段的至少一个重链可变结构域组成的多肽，其中所述VHH或其功能片段特异性结合存在于和/ 或特异于实体瘤，例如 HER2。本申请还提供了编码这种多肽的核酸; 制备此类多肽的方法; 表达或能够表达这种多肽的宿主细胞; 组合物，特别是药物组合物，其包含这种多肽，核酸和/或宿主细胞。本申请进一步提供了用于癌症的检测，成像，预后和诊断以及用于预测患者对治疗剂的反应的方法中的这些多肽，核酸，宿主细胞和/或组合物。

58. 发明申请

WO2016016021A1 RADIO-LABELLED ANTIBODY FRAGMENTS FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER 审中-公开
标题翻译：用于预防和/或治疗癌症的无线标签抗体片段
公开(公告)号：WO2016016021A1
公开(公告)日：2016-02-04
申请号：PCT/EP2015/066430
申请日：2015-07-17
申请人： VRIJE UNIVERSITEIT BRUSSEL
发明人： LAHOUTTE, Tony , DEVOOGDT, Nick , D'HUYVETTER, Matthias , DE VOS, Jens
IPC分类号： A61K51/10 , A61P35/00
CPC分类号： A61K51/1045 , A61K9/0019 , A61K51/1051 , A61K51/1069 , A61K51/1072 , A61K51/1078 , A61K51/1096 , C07K16/32 , C07K2317/56 , C07K2317/76 , C07K2317/92
摘要： The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (V HH ) or functional fragments thereof, wherein said V HH or functional fragment thereof specifically binds to a target protein that is present on and/or specific for a solid tumor or cancer cell, e.g. HER2. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions that comprise such polypeptides, nucleic acids and/or host cells. The application further provides such polypeptides, nucleic acids, host cells and/or compositions,for use in methods for the prevention and/or treatment of cancer.
摘要翻译：该应用提供包含或基本上由至少一个重链抗体（VHH）的重链可变区或其功能片段组成的多肽，其中所述VHH或其功能片段特异性结合存在于和/或特异性的靶蛋白用于实体肿瘤或癌细胞，例如 HER2。本申请还提供了编码这种多肽的核酸; 制备此类多肽的方法; 表达或能够表达这种多肽的宿主细胞; 组合物，特别是包含这种多肽，核酸和/或宿主细胞的药物组合物。本申请还提供了用于预防和/或治疗癌症的方法中使用的这种多肽，核酸，宿主细胞和/或组合物。

59. 发明申请

WO2015089283A1 ANTIBODIES THAT BIND ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译：抗体可激活抗体及其使用方法
公开(公告)号：WO2015089283A1
公开(公告)日：2015-06-18
申请号：PCT/US2014/069747
申请日：2014-12-11
申请人： CYTOMX THERAPEUTICS, INC.
发明人： DESNOYERS, Luc Roland , LIANG, Tony W. , WEAVER, Annie Y.
IPC分类号： C07K16/00 , C07K16/42 , G01N33/68 , C07K16/28 , C07K19/00
CPC分类号： A61K51/1078 , A61K2039/505 , C07K16/00 , C07K16/2863 , C07K16/2896 , C07K16/42 , C07K16/4291 , C07K2317/24 , C07K2317/34 , C07K2317/76 , C07K2319/00 , C07K2319/50 , G01N33/6854
摘要： The invention relates generally to antibodies and antigen-binding fragments thereof that bind activatable antibodies and/or conjugated activatable antibodies and methods of making and using these antibodies that bind activatable antibodies and/or conjugated activatable antibodies.
摘要翻译：本发明一般涉及结合可激活抗体和/或可共轭可激活抗体的抗体及其抗原结合片段，以及制备和使用这些结合可激活抗体和/或可共轭活化抗体的抗体的方法。

60. 发明申请

WO1993015405A1 CARCINOMA ASSOCIATED ANTIGEN (SK1) MONOCLONAL ANTIBODIES AGAINST SK1, METHODS OF PRODUCING THESE ANTIBODIES AND USE THERFOR 审中-公开
标题翻译： CARCINOMA相关抗原（SK1）抗SK1的单克隆抗体，生产这些抗体的方法及其用途
公开(公告)号：WO1993015405A1
公开(公告)日：1993-08-05
申请号：PCT/US1993000993
申请日：1993-01-28
申请人： SCI-CLONE, INC. , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： SCI-CLONE, INC. , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , GLASSY, Mark, C. , CHANG, Helena, R. , KODA, Keiji
IPC分类号： G01N33/574
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , A61K47/51 , A61K51/1045 , A61K51/1078 , A61K2121/00 , C07K16/30 , C07K16/42
摘要： Carcinoma associated antigen (SK1) and monoclonal antibodies and methods for detecting and ameliorating malignant disease. The monoclonal antibodies are specifically reactive with epitopes present on SK1.
摘要翻译：癌相关抗原（SK1）和单克隆抗体以及检测和改善恶性疾病的方法。单克隆抗体与SK1上存在的表位特异性反应。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式